📰 Medication Guide News
Medication Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.
June 7, 2024
Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status Durable and sustained red blood cell...
June 2, 2024
Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide
June 2, 2024
02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of ...
May 31, 2024
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma ...
May 23, 2024
Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with difficult-to-treat lymphomas across multiple lines of therapy
May 21, 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris
May 17, 2024
- AbbVie will present 15 abstracts, including three oral presentations, in Crohns disease and ulcerative colitis reinforcing AbbVies commitment to advancing...
May 16, 2024
Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term...
May 7, 2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1...
April 30, 2024
New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year…